Most Recent
Global pharmaceutical giant Lundbeck has launched a bid to escape a prior undertaking blocking it from appealing a court's decision that allowed four generic drug makers to apply for licences to manufacture generic versions of popular antidepressant Lexapro.
Litigation funder Litigation Capital Management will snap up 30 percent of a confidential settlement amount that KPMG has fought to keep under wraps in a shareholder class action over a failed $830 million hostile takeover bid of mining firm Discovery Metals.
A settlement has been reached in a class action against KPMG alleging it providing a misleading expert report to copper miner Discovery Metals that was used to reject a $830 million hostile takeover bid.
Two Adero Law-led class actions against Hays Specialist Recruitment and Stellar Personnel have been put on hold amid a looming Full Court appeal by Workpac which is expected to clarify the definition of casual work in Australia.
GetSwift shareholders Clutterbuck Capital Management and KPT Capital have opted out of a class action against the logistics services provider, blasting the "inappropriate and questionable" actions by some involved in the class action proceedings.
Australia's richest person Gina Rinehart has lost a bid to dismiss prior court orders to produce documents relating to the $4 billion family trust to her daughter, Bianca Rinehart.
A 2014 bushfire sparked by a termite-infested electrical pole that destroyed 57 homes was the fault of sub-contractor Thiess Services and the owner of the land on which the pole sat, a court has found.
AFT Pharmaceuticals has accused rival Reckitt Benckiser of using the court as a "clearance house" to beat its competitors, the latest development in a long-running dispute over AFT's Maxigesic ads.
Electricity retailer Click Energy has been ordered to pay $900,000 in penalties for misleading consumers about discounts on their energy bills.
Pharmaceutical giant Mylan has been ordered to hand over documents relating to its proposed launch of a generic version of its cholesterol drug Lipidil to rival Sun Pharma in advance of a hearing on Mylan's request for an order blocking Sun from launching its own generic version of the drug.